Neoplasms, Breast Clinical Trial
Official title:
An Open-label, Single-arm, Multi-centre, Phase II Study of Oral Lapatinib in Combination With Paclitaxel as First-line Treatment for ErbB2-amplified Metastatic Breast Cancer Patients
This study investigates the safety and efficacy of oral lapatinib in combination with an approved medication, paclitaxel, for patients with ErbB2 metastatic breast cancer.
n/a
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT00251433 -
GW572016 With Docetaxel and Trastuzumab for the Treatment Of Untreated ErbB2 Over-Expressing Metastatic Breast Cancer
|
Phase 1 | |
| Completed |
NCT01271738 -
Evaluating and Comparing Two Surgical Methods for Treatment of Early Stage Breast Cancer
|
N/A | |
| Recruiting |
NCT04892342 -
Study of ESG401 in Adults With Solid Tumors
|
Phase 1/Phase 2 | |
| Terminated |
NCT02213042 -
Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer
|
Phase 2 | |
| Withdrawn |
NCT01137994 -
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer
|
Phase 2 | |
| Completed |
NCT00790816 -
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
|
Phase 1 | |
| Completed |
NCT00051103 -
Oral Drug Study In Women With Refractory Metastatic Breast Cancer After First-line or Second-line Herceptin.
|
Phase 2 | |
| Completed |
NCT00320411 -
GW572016 In Patients With ErbB2 Over - Expressing Advanced Or Metastatic Breast Cancer
|
Phase 2 | |
| Completed |
NCT00258050 -
To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients
|
Phase 1 | |
| Terminated |
NCT01498588 -
Trial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer
|
Phase 2 | |
| Terminated |
NCT00479856 -
Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer
|
Phase 2 | |
| Completed |
NCT00320385 -
Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer
|
Phase 3 | |
| Completed |
NCT00062686 -
GW572016 For Treatment Of Refractory Metastatic Breast Cancer
|
Phase 2 | |
| Completed |
NCT00996762 -
A Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib
|
Phase 1 | |
| Terminated |
NCT02913729 -
Pre- Versus Postoperative Accelerated Partial Breast Irradiation
|
N/A | |
| Completed |
NCT01160211 -
A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer
|
Phase 3 | |
| Recruiting |
NCT05814224 -
Monitoring luminAl Breast Cancer Through the Evaluation of Mutational and epiGeNEtic alteraTIons of Circulating ESR1 DNA
|
N/A | |
| Completed |
NCT01815294 -
A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer
|
Phase 1 | |
| Terminated |
NCT00437073 -
Brain Metastases In ErbB2-Positive Breast Cancer
|
Phase 2 | |
| Completed |
NCT00490139 -
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D
|
Phase 3 |